Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 4, 2014

View Archived Issues

Atreca and Janssen Biotech collaborate in autoimmune diseases

Nuvilex to develop treatments that combine Cell-in-a-Box and cannabinoid-based medicine

First patient dosed in phase Ia trial of SYN-004 for the prevention of C. difficile infection

Evotec and Sanofi propose major strategic alliance to accelerate drug discovery

Imugene updates preclinical findings for HER-Vaxx

Novel CDK4/6 inhibitor is active in models of rheumatoid arthritis

Compugen reports results for drug target candidate identified through new methodology

Launch of Glanatek Ophthalmic Solution, a new treatment for glaucoma and ocular hypertension

Phase I results reported for glioma vaccine SurVaxM

Peloton Therapeutics conducts phase I trial of PT-2385 in advanced ccRCC

Astellas to end license agreement with Janssen for ASP-015K

Discovery of a novel MAb able to inhibit sporozoite invasion of hepatocytes in vivo

Epirus Biopharmaceuticals launches infliximab biosimilar in India

Aeterna Zentaris and Sinopharm A-Think sign Chinese license agreement for zoptarelin doxorubicin

Johns Hopkins University patents novel proteasome inhibitors

Italy researchers prepare new FXR modulators

Janssen R&D Ireland discloses novel anti-HBV compounds

First-in-human results presented for the DVD-Ig ABT-122

New CPT-1 inhibitors designed at the University of Aberdeen

Merck Patent reports new DNA-PK inhibitors

Update on FDA orphan drug status designations

Shandong International Biotechnology Park and MRC Technology to co-develop Alzheimer's disease drug

Inhibition of GBP1:PIM1 interaction, a potential target to overcome paclitaxel resistance

Targovax to develop melanoma vaccine using prize funds

Sprint Bioscience's Vps34 inhibitors reduce tumor growth in breast cancer model

FDA approves Blincyto to treat relapsed or refractory B-cell precursor ALL

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...